^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    GLPG 1790

    i
    Other names: GLPG 1790, GLPG1790, GLPG-1790
    Associations

    News

    Trials
    Company:
    Galapagos
    Drug class:
    EphA2 receptor antagonist
    Related drugs:
    Associations

    News

    Trials
    over4years
    Antitumorigenic Effects of Inhibiting Ephrin Receptor Kinase Signaling by GLPG1790 against Colorectal Cancer Cell Lines In Vitro and In Vivo. (PubMed, J Oncol)
    Finally, GLPG1790 hindered the epithelial-mesenchymal transition, reduced the migratory capacities of CRC, and affected tumor formation in xenograft models in vivo more efficiently using HCT116 than HCT15 for xenografts. Taken together, our data suggest the therapeutic potential of GLPG1790 as a signal transduction-based therapeutic strategy in to treat CRC.
    Preclinical • Journal
    |
    CCNE1 (Cyclin E1) • EPHA2 (EPH receptor A2) • PCNA (Proliferating cell nuclear antigen)
    |
    GLPG 1790